Translate this page into:
Novel 2-aminoimidazole-4-one complexes of copper(II) and cobalt(II): Synthesis, structural characterization and cytotoxicity
⁎Corresponding author. bel@org.chem.msu.ru (Elena K. Beloglazkina)
-
Received: ,
Accepted: ,
This article was originally published by Elsevier and was migrated to Scientific Scholar after the change of Publisher.
Peer review under responsibility of King Saud University.
Abstract
A series of 2-aminosubstituted (5Z)-3-phenyl-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-ones (L) was prepared by the reaction of the corresponding 2-alkylthio-3,5-dihydro-4H-imidazole-4-ones with morpholine or piperidine in the presence of ytterbium(III) triflate. The resulting ligands were subsequently reacted with CuCl2·2H2O and CoCl2·6H2O to give the corresponding copper(II) and cobalt(II) complexes, respectively. Analysis revealed that the complexes were formed with an LMCl2 (M = Cu, Co)-type composition in all cases. The structures of the three cobalt complexes prepared in this way were determined by X-ray crystallography. The results revealed that the cobalt ions in these complexes were tetrahedrally coordinated to two chloride anions and two nitrogen atoms from the pyridine and imidazole moieties of the ligand. The electrochemical properties of the ligands and their complexes were evaluated by cyclic voltammetry, and the results revealed that the first stage in the reduction of the Co(II) and Cu(II) complexes involved the reversible formation of the corresponding Co(I) and Cu(I) complexes, respectively. The cytotoxicity activities of the organic ligands and their complexes were evaluated against several cancer cell lines, including MCF-7, A549 and HEK293 cells. The copper complexes of the organic ligands bearing a phenyl or allyl moiety at their N(3) position together with a piperidine substituent at the 2-position of their imidazolone ring exhibited the greatest cytotoxicity of all of the compounds tested in the current study.
Keywords
Cobalt(II) complexes
Copper(II) complexes
2-Aminoimidazole-4-ones
Cytotoxicity
1 Introduction
Despite its high neuro- and nephrotoxicity, cisplatin is still one the most commonly used anticancer drugs in clinical practice (Anderson et al., 1990; Ries and Klastersky, 1986). In contrast to platinum, copper is an endogenous metal that is necessary for normal cellular activity. For example, copper is found in several important enzymes, including eukaryotic copper amine oxidase (Parsons et al., 1995), NO-reductase (Gardner et al., 2002; Oshima et al., 2005) and superoxide dismutase (Konecny et al., 1999; Tainer and Getzoff, 1982). It is therefore envisaged that copper complexes will be less toxic than the corresponding platinum-based anticancer compounds (Du et al., 2014). Bisthiosemicarbazone (Williams and Faulkner, 1996), phenanthroline (Sharma et al., 1980; de Vizcaya-Ruiz et al., 2000) and several other (Santini et al., 2014) copper complexes have been reported to show high levels of cytotoxicity against numerous cancer cell lines, and some of these complexes are currently being evaluated in clinical trials (Kang et al., 2009; Pickart, 2008).
We recently discovered a series of cytotoxic copper complexes based on 2-thiohydantoin derivatives, namely (5Z)-(5-pyridylmethylene)-2-alkylthioimidazole-4-ones (Majouga et al., 2014). These complexes exhibited cytotoxic activity against several cancer cell lines, including HEK-293 (transformed human embryonic kidney), SiHa (cervical cancer) and MCF-7 (breast cancer) cells. It has been reported that 2-thiohydantoin-containing complexes are one of very few classes of copper complex that can be visualized in cell nuclei in their non-dissociated form (Majouga et al., 2014), affording a unique opportunity for the targeted delivery of cytotoxic compounds into cells. To further investigate the structure-activity relationship of the copper complexes of 5-pyridylmethylene-imidazole-4-ones we have synthesized a series of copper complexes based on the structurally similar 2-amino-imidazole-4-ones. In contrast to our previously reported ligands, these new systems contain a nitrogen substituent at the 2-position of their imidazoline ring instead of a sulfur atom. We have also prepared a series of structurally related cobalt(II) complexes of 5-pyridylmethylene-2-amino-imidazol-4-one ligands.
2 Experimental part
2.1 Materials and methods
All of the samples were prepared in reagent grade solvents. All of the chemicals used to synthesize the ligands were obtained from Acros or Sigma Aldrich and used as received without further purification. All of the reactions were monitored by thin-layer chromatography on Silufol precoated silica gel plates (with fluorescence indicator UV254) using a 1:1 (v/v) mixture of ethyl acetate and n-hexane as the solvent system. Melting point (mp) data were obtained in open capillaries on an SMP11 Stuart melting point apparatus and are uncorrected. Elemental analyses were conducted on a Vario MICRO cube CHNS/O Elementar system (Vario). 1H and 13C NMR spectra were recorded on a Bruker Avance 400 (400 MHz) spectrometer using CDCl3 or (CD3)2SO as a solvent. NMR data have been reported in the following order: chemical shift (δ) value in ppm relative to the solvent resonance, which was used as an internal reference standard; and coupling constant (J) in Hertz (Hz). X-ray diffraction analysis was conducted on a CAD4 diffractometer at 293 K (graphite monochromated radiation, (MoKα) = 0.71073 Å, ω/1.33θ scan type). The 2-methylthio-imidazole-4-one starting materials were synthesized according to previously published methods from the literature (Beloglazkina et al., 2005a,b; Majouga et al., 2004a,b; Majouga et al., 2014; Mironov et al., 2013).
Electrochemical studies were carried out on a PI-50-1.1 potentiostat in MeCN. A 0.05 M solution of Bu4NClO4 in MeCN was used as a supporting electrolyte, with Ag/AgCl/KCl (saturated) as a reference electrode. All of these measurements were conducted under an atmosphere of argon. The samples were dissolved in previously de-aerated solvents.
2.2 Morpholine-substituted ligands
2.2.1 General procedure
Morpholine (2 ml) and a catalytic amount of ytterbium(III) triflate (5 mol%) were added to 3-substituted-5-((Z)-2-pyridylmethylene)-2-methylthioimidazole-4-one. The reaction mixture was boiled until none of reagents were observed by TLC. The reaction mixture was evaporated to dryness, then EtOH (1 ml) was added and the obtained precipitate was filtered off and recrystallized from ethanol.
2.2.1.1 (5Z)-3-phenyl-2-(morpholine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one (1)
The reaction of 0.207 g (0.7 mmol) (5Z)-3-phenyl-5-(2-pyridylmethylene)-2-methylthiotetrahydro-4H-imidazole-4-one with morpholine yielded 0.118 g (50%) of compound 1. M. p. 223 °C. 1H NMR (CDCl3): 8.78 (s, 1H, Hα-Py), 8.64 (d, 1H, J = 8.8 Hz, Hβ-Py), 7.80 (t, 1H, J = 8.0 Hz, Hγ-Py), 7.56–7.42 (m, 5H, Ph), 7.23 (t, 1H, J = 6.4 Hz, Hβ-Py), 7.00 (s, 1H, HC⚌), 3.90 (s, 4H, CH2OCH2), 3.70 (m, 4H, CH2NCH2). IR (cm−1): 1730 (C⚌O), 1630 (C⚌N), 1590 (C⚌C). Elemental analysis: C19H18N4O2 calculated: C 68.26%, H 5.38%, N 16.76%; found: C 68.30%, H 5.49%, N 16.48%.
2.2.1.2 (5Z)-3-methyl-2-(morpholine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one (2)
The reaction of 0.2 g (0.86 mmol) (5Z)-3-methyl-5-(2-pyridylmethylene)-2-methylthiotetrahydro-4H-imidazole-4-one with morpholine yielded 0.150 g (64%) of compound 2. M. p. 155 °C. 1H NMR (CDCl3): 8.82 (s, 1H, Hα-Py), 8.58 (d, 1H, J = 7.2 Hz, Hβ-Py), 7.80 (t, 1H, J = 6.4 Hz, Hγ-Py), 7.23 (t, 1H, J = 5.2 Hz, Hβ-Py), 6.93 (s, 1H, HC⚌), 3.89 (s, 4H, CH2OCH2), 3.73 (s, 4H, CH2NCH2), 3.30 (s, 3H, NCH3). IR (cm−1): 1720(C⚌O), 1640 (C⚌N), 1600 (C⚌C). Elemental analysis: C14H16N4O2 calculated: C 61.76%, H 5.88%, N 20.59%; found: C 61.65%, H 5.86%, N 20.64%.
2.2.1.3 (5Z)-3-allyl-2-(morpholine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one (3)
The reaction of 0.133 g (0.52 mmol) (5Z)-3-allyl-5-(2-pyridylmethylene)-2-methylthiotetrahydro-4H-imidazole-4-one with morpholine yielded 0.11 g (71%) of compound 3. M. p. 148 °C. 1H NMR (CDCl3): 8.82 (s, 1H, Hα-Py), 8.57 (s, 1H, Hβ-Py), 7.80 (s, 1H, Hγ-Py), 7.22 (s, 1H, Hβ-Py), 6.94 (s, 1H, HC⚌), 5.93 (m, 1H, HC⚌), 5.27 (m, 2H, H2C⚌), 4.34 (m, 2H, CH2), 3.86 (m, 4H, CH2OCH2), 3.73 (s, 4H, CH2NCH2). IR (cm−1): 1740 (C⚌O), 1630 (C⚌N), 1660 (C⚌C), 1600 (C⚌C). Elemental analysis: C16H18N4O2 calculated: C 64.43%, H 6.04%, N 18.79%; found: C 64.11%, H 6.08%, N 18.61%.
2.2.1.4 (5Z)-3-(2-azidoethyl)-2-(morpholine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one (4)
The reaction of 0.2 g (0.86 mmol) (5Z)-3-azidoethyl-5-(2-pyridylmethylene)-2-methylthiotetrahydro-4H-imidazole-4-one with morpholine yielded 0.202 g (46%) of compound 4. 1H NMR (CDCl3): 8.67 (d, 1H, J = 8.0 Hz, Hα-Py), 8.64 (dt, 1H, J1 = 4.8 Hz, J2 = 0.8 Hz, Hβ-Py), 7.72 (dt, 1H, J1 = 7.91 Hz, J2 = 1.82 Hz, Hγ-Py), 7.18–7.14 (m, 1H, Hβ-Py), 6.99 (s, 1H, HC⚌), 3.91–3.85 (m, 4H, CH2OCH2), 3.81 (dd, 2H, J1 = 9.13 Hz, J2 = 3.2 Hz, CH2N3), 3.73 (t, 2H, J = 5.7 Hz, CH2CH2N3), 3.66–3.61 (m, 4H, CH2NCH2). IR (cm−1): 2114 (N3), 1718 (C⚌O), 1639 (C⚌C). Elemental analysis: C15H17N7O2 calculated: C 55.04%, H 5.23%, N 29.95%; found: C 54.90%, H 5.28%, N 29.91%.
2.3 Piperidine-substituted ligands
2.3.1 General procedure
Piperidine (4.3 ml) and a catalytic amount of ytterbium(III) triflate (5 mol%) were added to 3-substituted (5Z)-(5-pyridylmethylene)-2-methylthio-imidazole-4-one. The reaction mixture was boiled until none of starting reagents was seen on TLC. The reaction mixture was evaporated to dryness, then diethyl ether was added and the obtained precipitate was filtered off and recrystallized from ethanol.
2.3.1.1 (5Z)-3-phenyl-2-(piperidine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one (5)
The reaction of 0.2 g (0.86 mmol) (5Z)-3-phenyl-5-(2-pyridylmethylene)-2-methylthiotetrahydro-4H-imidazole-4-one with piperidine yielded 0.202 g (71%) of compound 5. M. p. 220 °C. 1H NMR (CDCl3): 8.68 (m, 2H, Hα-Py + Hβ-Py), 7.77 (t, 1H, J = 8.2 Hz, Hγ-Py), 7.53–7.47 (m, 5H, Ph), 7.16 (t, 1H, J = 6.0 Hz, Hβ-Py), 6,94 (s, 1H, HC⚌), 3.39 (m, 4H, CH2NCH2), 1.66–1.50 (m, 6H, CH2CH2NCH2CH2CH2). Elemental analysis: C20H20N4O2 calculated: C 72.29%, H 6.02%, N 16.87%; found: C 72.61%, H 6.22%, N 16.75%.
2.3.1.2 (5Z)-3-methyl-2-(piperidine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one (6)
The reaction of 0.2 g (0.86 mmol) (5Z)-3-methyl-5-(2-pyridylmethylene)-2-methylthiotetrahydro-4H-imidazole-4-one with piperidine yielded 0.190 g (82%) of compound 6. M. p. 140 °C. 1H NMR (CDCl3): 8.70 (d, 1H, J = 8.0 Hz, Hα-Py), 8,65 (d, 1H, J = 4.40 Hz, Hβ-Py), 7.73 (dt, 1H, J1 = 7.6 Hz, J2 = 1.6 Hz, Hγ-Py), 7.14 (m, 1H, Hβ-Py), 6.91 (s, 1H, HC⚌), 3.6 (m, 4H, CH2NCH2), 3,28 (s, 3H, CH3), 1.76 (m, 6H, CH2CH2NCH2CH2CH2). IR (cm−1): 1715 (C⚌O), 1627 (C⚌N), 1589 (C⚌C). Elemental analysis: C15H18N4O2 calculated: C 66.67%, H 6.67%, N 20.74%; found: C 66.68%, H 6.89%, N 20.48%.
2.3.1.3 (5Z)-3-allyl-2-(piperidine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one (7)
The reaction of 0.134 g (0.52 mmol) (5Z)-3-allyl-5-(2-pyridylmethylene)-2-methylthiotetrahydro-4H-imidazole-4-one with piperidine yielded 0.154 g (61%) of compound 7. M. p. 172 °C. 1H NMR (CDCl3): 79 (s, 1H, Hα-Py), 8.64 (s, 1H, Hβ-Py), 7.80 (s, 1H, Hγ-Py), 7.20 (s, 1H, Hβ-Py), 6.88 (s, 1H, HC⚌), 5.94 (m, 1H, HC⚌), 5.26 (m, 2H, H2C⚌), 4.31 (m, 2H, CH2), 3.65 (m, 4H, CH2NCH2), 1.75 (m, 6H, CH2CH2NCH2CH2CH2). IR (cm−1): 1740 (C⚌O), 1625 (C⚌N), 1649 (C⚌C), 1598 (C⚌C). Elemental Analysis: C17H20N4O2 calculated: C 68.92%, H 6.76%, N 18.92%; found: C 68.55%, H 6.70%, N 18.79%.
2.3.1.4 (5Z)-3-(2-azidoethyl)-2-(piperidine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one (8)
The reaction of 0.05 g (0.17 mmol) (5Z)-3-(2-azidoethyl)-5-(2-pyridylmethylene)-2-methylthiotetrahydro-4H-imidazole-4-one with piperidine yielded 0.0325 g (58%) of compound 8. 1H NMR (CDCl3): 8.71 (dt, 1H, J1 = 8.1 Hz, J2 = 0.9 Hz, Hα-Py) 8.62 (d, 1H, J = 4.8 Hz, Hβ-Py), 7.71 (dt, 1H, J1 = 7.8 Hz, J2 = 1.8 Hz, HY-Py) 7.13 (ddd, 1H, J1 = 7.4 Hz, J2 = 4.8 Hz, J3 = 1.1 Hz, Hβ-Py), 6.92 (s, 1H, HC⚌), 3.80 (t, 2H, J = 6.4 Hz, CH2N3), 3.69 (t, 2H, J = 6.2 Hz, CH2), 3.55 (m, 4H, CH2NCH2), 1.76 (s, 6H, CH2CH2NCH2CH2CH2). IR (cm−1): 2080 (N3), 1730 (C⚌O), 1660 (C⚌C). Elemental analysis: C16H19N7O calculated: C 59.06%, H 5.89%, N 30.13%; found: C 59.36%, H 5.99%, N 29.81%.
2.4 Coordination compounds
To the solution of ligand 1–8 in 1 ml of CH2Cl2 the solution of equimolar amount of CuCl2·2H2O or CoCl2·6H2O in 1 ml of n-BuOH was carefully added and the mixture was left in a closed vessel until precipitation. The forming dark green crystals were filtered off and dried in air.
2.4.1 (5Z)-3-phenyl-2-(morpholine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II) dichloride (1a)
Complex 1a was obtained from 10 mg (0.03 mmol) of compound 1 and 5.3 mg (0.03 mmol) CuCl2·2H2O. Yield 3 mg (22%). Elemental analysis: C19H18N4O2CuCl2 calculated: C 48.67%, H 3.84%, N 11.95%; found: C 48.92%, H 3.80%, N 11.92%.
2.4.2 (5Z)-3-methyl-2-(morpholine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II) dichloride (2a)
Complex 2a was obtained from 10 mg (0.037 mmol) of compound 2 and 6.3 mg (0.037 mmol) CuCl2·2H2O. Yield 3 mg (20%). Elemental analysis: C14H16N4O2CuCl2 calculated: C 41.33%, H 3.94%, N 13.78%; found: C 41.50%, H 4.15%, N 13.56%.
2.4.3 (5Z)-3-allyl-2-(morpholine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II) dichloride (3a)
Complex 3a was obtained from 10 mg (0.036 mmol) of compound 3 and 5.7 mg (0.036 mmol) CuCl2·2H2O. Yield 3.9 mg (25%). Elemental analysis: C16H18N4O2CuCl2 calculated: C 44.40%, H 4.19%, N 12.95%; found: C 44.26%, H 4.07%, N 13.07%.
2.4.4 (5Z)-3-(2-azidoethyl)-2-(morpholine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II) dichloride (4a)
Complex 4a was obtained from 28.7 mg (0.092 mmol) of compound 4 and 16 mg (0.092 mmol) CuCl2·2H2O. Yield 8.5 mg (20%). Elemental analysis: C15H17N7O2CuCl2 calculated: C 39.01%, H 3.71%, N 21.23%; found: C 39.19%, H 3.95%, N 21.33%.
2.4.5 (5Z)-3-phenyl-2-(piperidine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II) dichloride (5a)
Complex 5a was obtained from 20 mg (0.06 mmol) of compound 5 and 10.2 mg (0.059 mmol) CuCl2·2H2O. Yield 7 mg (25%). Elemental analysis: C20H20N4OCuCl2 calculated: C 51.44%, H 4.29%, N 12.00%; found: C 51.60%, H 4.22%, N 11.99%.
2.4.6 (5Z)-3-methyl-2-(piperidine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II) dichloride (6a)
Complex 6a was obtained from 10 mg (0.037 mmol) of compound 6 and 8.8 mg (0.052 mmol) CuCl2·2H2O. Yield 3.4 mg (22%). Elemental analysis: C15H18N4OCuCl2 calculated: C 44.51%, H 4.48%, N 13.84%; found: C 44.39%, H 4.56%, N 13.89%.
2.4.7 (5Z)-3-allyl-2-(piperidine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II) dichloride (7a)
Complex 7a was obtained from 10 mg (0.034 mmol) of compound 7 and 5.8 mg (0.034 mmol) CuCl2·2H2O. Yield 3.7 mg (25%). Elemental analysis: C17H20N4OCuCl2 calculated: C 47.39%, H 4.65%, N 13.01%; found: C 47.32%, H 4.57%, N 13.22%.
2.4.8 (5Z)-3-(2-azidoethyl)-2-(piperidine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II) dichloride (8a)
Complex 8a was obtained from 16.3 mg (0.05 mmol) of compound 8 and 9 mg (0.05 mmol) CuCl2·2H2O. Yield 4.6 mg (20%). Elemental analysis: C16H19N2OCuCl2 calculated: C 41.79%, H 4.16%, N 21.32%; found: C 41.65%, H 4.21%, N 21.23%.
2.4.9 (5Z)-3-phenyl-2-(morpholine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II) dichloride (1b)
Complex 1b was obtained from 10 mg (0.03 mmol) of compound 1 and 7.2 mg (0.03 mmol) CoCl2·6H2O. Yield 3.3 mg (24%). Elemental analysis: C19H18N4O2CoCl2 calculated: C 49.15%, H 3.88%, N 12.08%; found: C 49.47 %, H 4.11 %, N 12.23%.
2.4.10 (5Z)-3-methyl-2-(morpholine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II) dichloride (2b)
Complex 2b was obtained from 10 mg (0.037 mmol) of compound 2 and 8.8 mg (0.037 mmol) CoCl2·6H2O. Yield 3.1 mg (21%). Elemental analysis: C14H16N4O2CoCl2 calculated: C 41.79%, H 3.98%, N 13.93%; found: C 41.60%, H 3.76%, N 13.73%.
2.4.11 (5Z)-3-allyl-2-(morpholine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II) dichloride (3b)
Yield 3.8 mg (24%). Complex 3b was obtained from 10 mg (0.036 mmol) of compound 3 and 8 mg (0.036 mmol) CoCl2·6H2O. Elemental analysis: C16H18N4O2CoCl2 calculated: C 44.88%, H 4.24%, N 13.08%; found: C 45.11 %, H 4.40%, N 12.99%.
2.4.12 (5Z)-3-(2-azidoethyl)-2-(morpholine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II) dichloride (4b)
Complex 4b was obtained from 28.7 mg (0.092 mmol) of compound 4 and 21.3 mg (0.092 mmol) CoCl2·6H2O. Yield 10.5 mg (25%). Elemental analysis: C15H17N7O2CoCl2 calculated: C 39.41%, H 3.75%, N 21.45%; found: C 39.44%, H 3.83%, N 21.32%.
2.4.13 (5Z)-3-phenyl-2-(piperidine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II) dichloride (5b)
Complex 5b was obtained from 10 mg (0.03 mmol) of compound 5 and 7.1 mg (0.059 mmol) CoCl2·6H2O. Yield 3.2 mg (24%). Elemental analysis: C20H20N4OCoCl2 calculated: C 51.96%, H 4.33%, N 12.12%; found: C 52.13%, H 4.39%, N 11.95%.
2.4.14 (5Z)-3-methyl-2-(piperidine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II) dichloride (6b)
Complex 6b was obtained from 10 mg (0.037 mmol) of compound 6 and 12.4 mg (0.052 mmol) CoCl2·6H2O. Yield 3.3 mg (23%). Elemental analysis: C15H18N4OCoCl2 calculated: C 45.01%, H 4.50%, N 14.00%; found: C 44.89%, H 4.34%, N 13.88%.
2.4.15 (5Z)-3-allyl-2-(piperidine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II) dichloride (7b)
Complex 7b was obtained from 10 mg (0.034 mmol) of compound 7 and 8.1 mg (0.034 mmol) CoCl2·6H2O. Yield 3 mg (20%). Elemental analysis: C17H20N4OCoCl2 calculated: C 47.90%, H 4.70%, N 13.15%; found: C 48.19%, H 4.95%, N 13.23%.
2.4.16 (5Z)-3-(2-azidoethyl)-2-(piperidine-1-yl)-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II) dichloride (8b)
Complex 8b was obtained from 16.3 mg (0.05 mmol) of compound 8 and 12 mg (0.05 mmol) CoCl2·6H2O. Yield 4.6 mg (21%). Elemental analysis: C16H19N2OCoCl2 calculated: C 42.22%, H 4.21%, N 21.54%; found: C 42.29%, H 4.35%, N 21.50%.
3 Results and discussion
Herein, we report the synthesis and characterization of a series of novel 2-aminosubstituted (5Z)-3-phenyl-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-ones and their copper(II) and cobalt(II) complexes. These ligands varied in terms of the structure of their amine moiety (i.e., morpholine or piperidine), as well as the nature of the substituent on their N(3) atom (i.e., phenyl, methyl, allyl or 2-azidoethyl). It is noteworthy that all of these ligands contained an azide group, making their complexes amenable to the preparation of covalent conjugates with both low molecular weight compounds and biopolymers using “click” chemistry.
3.1 Synthesis and characterization
The most commonly used approach for the synthesis to 2-amino-imidazole-4-ones involves the reaction of 2-thiohydantoins or their S-alkylated derivatives with an amine under heating (El-Barbary et al., 2000; Hu et al., 2002) or microwave irradiation (Asmaa et al., 2007). It is noteworthy that S-alkylated thiohydantoins have been reported to show better results in these reactions than 2-thiohydantoins (Carver et al., 1997; Grimmet, 1970; Lindel and Hoffmann, 1997; Roue and Bergman, 1999; Ybrahim et al., 1980). With this in mind, S-alkylated thiohydantoins were selected as starting materials for this study.
We initially investigated the reactions of 2-methylthio-substituted imidazolones with morpholine under reflux conditions. However, these conditions failed to afford the desired 2-morpholyl-substituted imidazolones 5–7 in yields greater than 10%. To increase the yields of the target amino-imidazolones we investigated the use of several Lewis acid catalysts, including AlCl3, ZnCl2 and Yb(OTf)3. The results revealed that AlCl3 and ZnCl2 did not catalyze the reaction, whereas the use of ytterbium(III) triflate led to a significant increase in the yields of the desired amino-substituted imidazolones to 46–82% (Scheme 1).
Compounds 3–6 were isolated as single geometric isomers, which were determined to the (Z)-isomers based on the chemical shifts and the coupling constants of the vinylic protons by 1H NMR spectroscopy (Mironov et al., 2013). The (Z)-configurations of ligands 2, 5 and 6 were also confirmed based on the X-ray diffraction analysis of the corresponding coordination complexes 2b, 5b and 6b (see below).
A series of Cu(II) and Co(II) complexes were prepared using the (5Z)-2-amino-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-ones prepared in the current study by the direct reaction of CH2Cl2 solutions of these ligands with copper(II) or cobalt(II) chloride, respectively (Scheme 2). All of the resulting complexes were characterized by elemental analysis. The coordination compounds 1a–6a, 1b, 2b, 4b, 7b and 8b were also characterized by UV/Vis spectroscopy. Characteristic low-intensity d–d transition bands were observed in the UV/Vis spectra of all of the coordination compounds prepared in the current study in the range of 550–720 nm (Fig. 1 and Supplementary information). These data were consistent with the literature data for the tetrahedral Cu(II) and Co(II) complexes of 2-substituted 5-pyridylmethylene-imidazol-4-ones (Beloglazkina et al., 2005a,b, 2006a,b; Majouga et al., 2004a,b, 2009, 2014). According to the literature (Guo et al., 2002; Rowland et al., 2000; Hennig et al., 1995, and previous references), the UV/Vis spectra of square planar copper(II) complexes should contain a broad band in the range of 550–750 nm, which would show a bathochromic shift upon tetrahedral distortion. The UV/Vis spectra of square planar cobalt complexes normally contain only one band in the visible region, whereas tetrahedral Co(II) complexes generally give three bands (or a broad band, representing the superposition of two overlapping bands) in this region (Van der Bergen et al., 1974; Beloglazkina et al., 2013). All of the complexes prepared in the current study also exhibited strong charge transfer bands in the UV region of their electronic spectra (see Supplementary information).

3.2 Molecular structures of complexes 2b, 5b and 6d
The structures of complexes 2b, 5b and 6b were confirmed by X-ray diffraction analysis, and the crystal structures are shown in Fig. 2. Selected bond lengths and bond angles from these crystal structures are shown in Tables 1 and 2. The previously reported (Majouga et al., 2004a,b) crystal structure of the cobalt complex of (5Z)-3-phenyl-2-methylthio-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one (complex A) is also shown in Fig. 1 for the sake of comparison. All of the crystallographic data and refinement parameters are shown in Tables S1, together with a list of bond lengths and bond angles. The cobalt ions in all of these complexes were tetrahedrally coordinated to the two nitrogen atoms of the pyridine and thiohydantoin rings and two chloride anions. The cobalt atoms were located in a distorted tetrahedral environment with Co—N distances of 2.032–2.040(10) Ǻ (Co—NPy) and 1.989–1.997(10) Ǻ (Co—NIm), which were similar to those observed in complex A (Majouga et al., 2004a,b). The phenyl substituent at the N(3) position of the ligand moiety in complex 5b was near perpendicular to the plane of the imidazolone ring. The piperidine and morpholine rings were found to exist in the chair conformations.
| Compound | Co—Cl1 | Co—Cl2 | Co—N(Py) | Co—N(Im) |
|---|---|---|---|---|
| 2b | 2.231(2) | 2.240(2) | 2.040(4) | 1.992(3) |
| 5b | 2.235(1) | 2.245(1) | 2.036(3) | 1.997(3) |
| 6b | 2.237(1) | 2.226(1) | 2.032(4) | 1.989(3) |
| A | 2.231(2) | 2.240(2) | 2.031(2) | 1.9262(19) |
| Compound | Cl1—Co—Cl2 | Cl1-—Co—N1 | Cl1—Co—N2 | Cl2—Co—N1 | Cl2—Co—N2 | N1—Co—N2 |
|---|---|---|---|---|---|---|
| 2b | 111.25(6) | 114.6(1) | 112.1(1) | 101.4(1) | 120.1(1) | 96.1(2) |
| 5b | 113.94(5) | 110.1(1) | 109.00(9) | 102.1(1) | 122.76(9) | 96.6(1) |
| 6b | 113.82(5) | 108.1(1) | 116.7(1) | 104.5(1) | 114.9(1) | 96.3(1) |
| A | 111.43(7) | 105.71(17) | 120.18(14) | 105.75(11) | 114.34(14) | 96.81(18) |
Consideration of the data in Tables 1 and 2 revealed that while the differences in the Co—N and Co—Cl bond lengths of the complexes of the 2-amino- and 2-thio-substituted imidazole-4-ones were negligible, the Cl1—Co—N2 bond angles differed considerable in these complexes. The tetrahedral coordination environment of the cobalt ions in the amino-substituted ligand complexes (2b, 5b, 6b) underwent much less distortion than the corresponding sulfur-containing (A) complexes. This difference was attributed to a higher level of steric hindrance around the metal ion of the 2-methylthio substituent compared with the corresponding 2-amino group.
3.3 Electrochemistry
Electrochemical studies were conducted using ligands 1, 2 and 7, together with their complexes, as representative examples by cyclic voltammetry (CV) using glassy carbon, platinum and gold electrodes. The results showed that all three of the ligands were reduced in two steps, the first of which was reversible with the second being irreversible (see Fig. 3 and Table 3). Ligand 1 bearing a phenyl substituent on its N(3) atom was reduced much more readily (i.e., 200 mV less cathodic) than the corresponding methyl- and allyl-substituted ligands 2 and 7, most likely because of the presence of the conjugated phenyl fragment.
| Compound | Electrode | EpRed, V | EpOx, V |
|---|---|---|---|
| 1 | Au | −1.33/−1.26 −1.84/−0.55 |
1.39 |
| GC | −1.37/−1.28 −1.87/−0.57 |
1.35 | |
| Pt | −1.37/−1.25 | 1.38 | |
| 2 | Au | −1.55/−1.48 −2.00/−0.78 |
1.14 1.58 |
| GC | −1.60/−1.48 −2.12/−0.75 |
1.14 1.51 |
|
| Pt | −1.60/−1.48 | 1.16 1.27 |
|
| 7 | Au | −1.47/−1.40 −1.97/−0.70 |
1.23 1.64 |
| GC | −1.46/−1.36 −2.04/−0.64 |
1.26 1.59 |
|
| Pt | −1.52/−1.42 | 1.19 | |
| 1a | Au | 0.25/0.42 −1.54/−1.47 −2.01 |
1.08 1.17 |
| GC | 0.15/0.24 −1.54 −2.10 |
1.21 | |
| Pt | 0.18/0.59 −1.56 |
1.24 | |
| 1b | Au | −0.96/−0.89 −1.51/−1.36 −2.01 |
1.09 1.23 |
| GC | −0.98/−0.91 −1.52/−1.39 −2.01 |
1.23 | |
| Pt | −0.96/−0.90 −1.62 |
1.30 | |
| 2a | Au | 0.24/0.37 −1.59 −1.84 |
1.12 1.27 |
| GC | 0.15/0.22 −1.62 −2.01 |
1.10 | |
| Pt | 0.17/0.37 −1.60 |
1.23 | |
| 2b | Au | −0.98/−0.90 −1.55/−1.44 |
1.06 1.15 1.31 |
| GC | −0.99/−0.92 −1.58 |
1.21 | |
| Pt | −1.00/−0.91 −1.61 |
1.26 | |
| 7a | Au | 0.26/0.41 −1.51/−1.38 |
1.19 1.30 |
| GC | 0.24/0.48 −1.58 |
1.20 | |
| Pt | 0.24/0.40 −1.53 |
1.23 | |
| 7b | Au | −0.90/−0.84 −1.47/−1.35 |
1.13 1.26 |
| GC | −0.89/−0.80 −1.48 |
1.21 | |
| Pt | −0.92/−0.85 −1.50/−1.36 |
1.26 | |
The oxidation reactions of compounds 1, 2 and 7 revealed that ligand 1 was irreversibly oxidized in a single-electron process, whereas compounds 2 and 7 were irreversibly oxidized in a two-electron process (Table 3, Fig. 3).
The cyclic voltammograms for cobalt complexes 1b and 2b contained additional peaks in the cathodic region for Epc values in the range of −0.89 to −1.0 V for all of the electrodes, corresponding to the reduction of Co(II) to Co(I) (Table 3, Fig. 4). The initial reduction of the cobalt complexes was found to be reversible at all of the electrodes. However, the intensity of the Co(II)/Co(I) re-oxidation peak for complex 2b was equal to about half of the reduction current over the Au and Pt electrodes. This result therefore suggested that the Co(I)-containing intermediates were stable on the timescale required for their analysis by CV, and that they were less stable on metal electrodes than the GC electrode.
The other peaks observed in the cathode region for the Co complexes were attributed to the reduction of the ligand fragments. These peaks were shifted slightly for complexes 2b and 7b relative to the corresponding peaks of the ligand, with the shift for complex 1b being the greatest of all (approximately 200 mV). These results indicate that the complexation of the ligands with cobalt leads to a change in the mechanism with which the ligand moiety is oxidized. This was confirmed by the fact that the first anodic peak for the complexes was a two-electron process.
The copper-containing complexes 1a–3a were reversibly reduced at potentials (Epc) in the range of 0.24–0.26 V (i.e., potentials around 200 mV). These potentials were less cathodic than those previously reported by our group for the thiohydantoin complexes of copper(II), which showed an Epc value of 0.45 V (Beloglazkina et al., 2005a).
The cyclic voltammograms showed that there were no desorption peaks corresponding to zero-valent copper on the GC or Pt electrodes, even under the reverse potential scan conditions after the oxidation and reduction of the ligand fragments. This result therefore indicated that the Cu(I)-containing intermediates were stable as complexes with both negatively and positively charged ligands. However, sharp triangular peaks (without a diffusion loop) were observed at the Au electrode for the copper-containing complexes 1a and 2a after the oxidation or reduction of the ligand moiety (Fig. 5), which were characteristic for the desorption of metallic copper from the electrode surface. It is therefore possible that the reduction intermediates (i.e., complexes of the negatively charged ligand (L−) with Cu(I)) could be unstable and disproportionate to give Cu(II) and Cu(0) complexes, with the latter of these two complexes decomposing with the release of metallic copper:

In contrast, any complexes formed with the positively charged ligands would be oxidized because of the low donor ability of the cationic ligand fragments.
It is noteworthy that no desorption peaks were observed for cycling potentials in the range of 0.1–0.65 V, which indicated the cobalt(I) complex formed with the neutral ligand was stable under these conditions.
3.4 Cytotoxicity
The ligands and the corresponding copper and cobalt complexes prepared in the current study were tested in terms of their in vitro cytotoxicity against cell cancer cells lines, including human lung cancer (A549), breast adenocarcinoma (MCF-7) and human embryonic kidney (HEK293) cells using a standard MTT assay (Mosmann, 1983). The results of this assay are shown in Table 4 together with the results obtained for the clinically used drugs cisplatin and doxorubicin, which have been included for comparison.
| Compound | A549, μM | MCF7, μM | HEK293T, μM |
|---|---|---|---|
| 1 | >200 | >200 | 111.41 ± 40.59 |
| 1a | 45.94 ± 6.5 | 32.3 ± 9.4 | 19.85 ± 6.35 |
| 1b | >200 | 131.04 ± 32.57 | >200 |
| 2 | >200 | 97.25 ± 19.56 | 183.20 ± 48.00 |
| 2a | >60 | 84.25 ± 11.4 | 36.41 ± 10.16 |
| 2b | >200 | 139.26 ± 48.05 | 126.74 ± 30.36 |
| 3 | >200 | >200 | 151.10 ± 36.50 |
| 3a | 57.81 ± 0.55 | 45.13 ± 0.04 | 29.39 ± 14.04 |
| 3b | 168.30 ± 31.30 | 140.40 ± 38.10 | 108.25 ± 17.25 |
| 5 | >200 | >200 | 167.32 ± 81.09 |
| 5a | 19.00 ± 5.11 | 15.88 ± 0.14 | 7.98 ± 1.87 |
| 5b | 119.80 ± 16.50 | 122.02 ± 38.39 | 121.0 ± 40.0 |
| 6 | >200 | >200 | 155.55 ± 43.65 |
| 6a | 32.57 ± 3.99 | 22.00 ± 3.91 | 10.58 ± 1.15 |
| 6b | 127.30 ± 17.90 | 87.28 ± 22.33 | 81.41 ± 12.10 |
| 7 | >200 | >200 | 111.41 ± 40.59 |
| 7a | 18.27 ± 1.42 | 13.67 ± 0.81 | 6.20 ± 0.33 |
| 7b | 137.95 ± 28.35 | 46.82 ± 13.63 | 117.96 ± 35.85 |
| Doxorubicinb | 2.0 ± 0.8 | 2.1 ± 0.8 | 1.1 ± 0.1 |
| Cisplatinb | >30 | 64.13 ± 3.9 | 12.4 ± 3.9 |
| CuCl2·2H2Oc | >100 |
The coordination of a metal ion was found to be essential for the cytotoxicity of the test compounds. For example, the IC50 values of the free ligands were much higher than those of the corresponding copper complexes. However, the cytotoxicities of the cobalt complexes were substantially lower than those of the corresponding copper complexes, although in some cases they were higher than those of the free ligands. The nature of the amine substituent at the 2 position of the imidazolone ring was also found to be important to the cytotoxicity of these compounds. For example, compounds containing a piperidine substituent (i.e., 5–7) were generally 1.5–2 times more active than compounds containing a morpholine residue at the same position (i.e., 1–3). The nature of the substituent at the N(3) position of the imidazolone ring also had a considerable impact on the cytotoxicity, which increased in the order Ph > Allyl > Me. This increase in the cytotoxicity correlates well with the increasing lipophilicity of the complexes.
HEK293 cells were found to be the most vulnerable of all the cell lines tested in the current study toward the test compounds, with complex 5a showing the greatest cytotoxicity of all of the test complexes. Furthermore, the cytotoxicity of complex 5a toward HEK293 cells was similar to that of cisplatin. The most active cobalt complexes were found to be compounds 1b and 7b. The cytotoxicities of these complexes toward MCF7 cells were 1.5 times greater than those of cisplatin.
Although the generation of reactive oxygen species (ROS) has been cited as a major contributory factor to the high toxicity and anticancer activity of numerous copper complexes (Hajrezaie et al., 2014; Mookerjee et al., 2006; Ng et al., 2014; Guo et al., 2010; Maheswari et al., 2008), we have assumed that the compounds described in this study do not induce the generation of ROS. This suggestion is supported by the lack of a correlation between the reduction potentials of these compounds and their cytotoxicity. All of the complexes prepared in the current study showed relatively low reduction potentials compared with those reported in our previous studies (Majouga et al., 2014), where we observed potentials around 0.45 V for the copper complexes of 2-thiohydantoin. The facile reduction of these complexes would facilitate their interaction with oxygen, which would enhance their cytotoxicity. However, this outcome was not observed, which suggested that the complexes prepared in the current study exert their cytotoxicity through a different mechanism.
4 Conclusions
In conclusion, we have prepared a novel series of nitrogen-containing bidentate organic ligands, together with their corresponding copper and cobalt complexes. These compounds have been fully characterized based on their NMR, IR, UV/Vis, elemental analysis and cyclic voltammetry data. Three cobalt complexes were also characterized by single-crystal X-ray analysis. The cytotoxicities of the copper containing complexes were comparable to those of cisplatin and doxorubicin against MCF-7, A549 and HEK293 cells. In contrast to many of other well-known metal-containing drugs, the mechanism of action of these complexes does not appear to include the formation of ROS.
Acknowledgments
The authors gratefully acknowledge the Ministry of Education and Science of the Russian Federation in the framework of Increase Competitiveness Program of NUST «MISiS» (# К1-2014-022) and Russian Foundation for Basic Research (Grant # 16-03-00921) for the financial support of this work.
References
- Protection against cisplatin toxicity by administration of glutathione ester. FASEB J.. 1990;14:3251-3255.
- [Google Scholar]
- A novel synthesis of some new imidazothiazole and glycocyamidine derivatives and studies on their antimicrobial activities. Phosphorus, Sulfur Silicon. 2007;182:529-536.
- [Google Scholar]
- Synthesis and electrochemistry of (5Z,5′Z)-2,2′-(alkane-α, ω-diyldisulfanyldiyl)-bis(5-(2-pyridylmethylene)-3,5-dihydro-4H -imidazol-4-one) complexes with cobalt(II) chloride. Russ. Chem. Bull., Int. Ed.. 2005;54:2163-2168.
- [Google Scholar]
- Synthesis and electrochemical study of complexes of 2-methylthio-5-(pyridylmethylidene)-3,5-dihydro-4H-imidazol-4-ones with transition metals (Co, Ni, and Cu). Molecular structures of CuIIL1Cl2 (L1 is (5Z)-2-methylthio-3-phenyl-5-(α-pyridylmethylidene)-3,5-dihydro-4H-imidazol-4-one) and CoIIL2Cl2(L2 is (5Z)-3-methyl-2-methylthio-5-(α-pyridylmethylidene)-3,5-dihydro-4H-imidazol-4-one) Russ. Chem. Bull., Int. Ed.. 2005;54:2771-2782.
- [Google Scholar]
- 5-(Pyridylmethylidene)-substituted 2-thiohydantoins and their complexes with CuII, NiII, and CoII: Synthesis, electrochemical study, and adsorption on the cystamine-modified gold surface. Russ. Chem. Bull., Int. Ed.. 2006;55:1015-1027.
- [Google Scholar]
- A novel catalyst for alkene epoxidation: a polymer-supported (CoLCl2)-L-II L = 2-(alkylthio)-3-phenyl-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imid azole-4-one complex. Tetrahedron Lett.. 2006;47:2957-2959.
- [Google Scholar]
- Novel copper(II) and cobalt(II) complexes with selenium substituted imidazolyl imines. The molecular and crystal structure of [N-(2-(phenylseleno)ethyl)-N-(imidazole-2-ylmethylene)amine]copper(II) dichloride. Polyhedron. 2013;50:425-433.
- [Google Scholar]
- Polyfunctionalisation of imidazole via sequential imidazolyl anion formation. Tetrahedron. 1997;53:14481-14496.
- [Google Scholar]
- Inhibitory act of selenoprotein P on Cu(+)/Cu(2+)-induced tau aggregation and neurotoxicity. Inorg. Chem.. 2014;53:11221-11230.
- [Google Scholar]
- Reaction of 2-thiohydantoin with some diazoalkanes and some amines. Phosphorus, Sulfur Silicon. 2000;160:77-91.
- [Google Scholar]
- Flavorubredoxin, an inducible catalyst for nitric oxide reduction and detoxification in Escherichia coli. J. Biol. Chem.. 2002;277:8172-8177.
- [Google Scholar]
- The synthesis of 2-Alkyl-and 2-Acyl-imidazoles by substitution methods. Adv. Heterocycl. Chem.. 1970;12:103-183.
- [Google Scholar]
- Structural and spectral studies of some coordination complexes of a phenol-functionalized diazamesocyclic ligand 1,4-bis-(3-tert-butyl-5-methyl-2-hydroxybenzyl)-1,4-diazacycloheptane (H2L) J. Mol. Struct.. 2002;643:77-82.
- [Google Scholar]
- ROS-mediated autophagy was involved in cancer cell death induced by novel copper(II) complex. Exp. Toxicol. Pathol.. 2010;62:577-582.
- [Google Scholar]
- Hajrezaie, M,. Paydar, M., Moghadamtousi, S.Z., Hassandarvish, P., Gwaram, N.S., Zahedifard, M., Rouhollahi, E., Karimian, H., Looi, C.Y., Ali, H.M., Majid, N.A., Abdulla, M.A., 2014. A Schiff Base-Derived Copper (II) Complex Is a Potent Inducer of Apoptosis in Colon Cancer Cells by Activating the Intrinsic Pathway. The Scientific World Journal.Article ID 540463 (<http://www.hindawi.com/journals/tswj/2014/540463/>).
- Transition metal complexes of quadridentate pyrazolo-based ligands with two thiolato and two imine donor atom. Inorg. Chim. Acta. 1995;234:67-74.
- [Google Scholar]
- New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J. Nat. Prod.. 2002;65:476-480.
- [Google Scholar]
- Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Arch. Dermatol. Res.. 2009;301:301-306.
- [Google Scholar]
- CuZn superoxide dismutase geometry optimization, energetics, and redox potential calculations by density functional and electrostatics methods. Inorg. Chem.. 1999;38:940-950.
- [Google Scholar]
- Synthesis of dispacamide from the marine sponge. Tetrahedron Lett.. 1997;38:8935-8938.
- [Google Scholar]
- Structure, cytotoxicity and DNA cleavage properties of the complex [CuII(pbt)Br 2] Inorg. Chem.. 2008;47:3719-3727.
- [Google Scholar]
- Synthesis, structure and electrochemistry of CoIILCl2.0.5CH3CN (L = [2-(methylthio)-3-phenyl-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-on]) Mend. Commun.. 2004;3:115-117.
- [Google Scholar]
- Synthesis of isomeric 3-phenyl-5-(pyridylmethylene)-2-thiohydantoins and their S-methylated derivatives. Molecular and crystal structures of (5Z)-3-phenyl-5-(pyridin-2-ylmethylene)-2-thiohydantoin and (5Z)-2-methylthio-3-phenyl-5-(pyridin-2-ylmethylene)-3,5-dihydro-4H-imidazol-4-one. Russ. Chem. Bull., Int. Ed.. 2004;53:2850-2855.
- [Google Scholar]
- Tetradentate nitrogen-containing ligands bis-5-(2-pyridylmethylidene)-3,5-dihydro-4H-imidazol-4-ones and their coordination compounds with CuI and CuII. Russ. Chem. Bull., Int. Ed.. 2009;58:1392-1399.
- [Google Scholar]
- Mixed valence copper(I, II) binuclear complexes with unexpected structure: synthesis, biological properties and anticancer activity. J. Med. Chem.. 2014;57:6252-6258.
- [Google Scholar]
- Structure determination of bis{(4Z)-1-(2-azidoethyl)-4-[(pyridin-2-yl)methylidene]-2-thiolatoimidazol-5(4H)-one}dicopper chloride from X-ray powder diffraction data. Russ. Chem. Bull., Int. Ed.. 2013;62:672-677.
- [Google Scholar]
- Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983;65:55-63.
- [Google Scholar]
- A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo. BMC Cancer. 2006;6:267.
- [CrossRef] [Google Scholar]
- Selective anticancer copper(II)-mixed ligand complexes: targeting of ROS and proteasomes. Metallomics. 2014;6:892-906.
- [Google Scholar]
- Structural evidence for direct hydride transfer from NADH to cytochrome P450nor. J. Mol. Biol.. 2005;342:207-217.
- [Google Scholar]
- Crystal structure of a quinoenzyme: copper amine oxidase of Escherichia coli at 2 A resolution. Structure. 1995;3:1171-1184.
- [Google Scholar]
- The human tri-peptide GHK and tissue remodeling. J. Biomater. Sci. Polym. Edn.. 2008;19:969-988.
- [Google Scholar]
- Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am. J. Kidney Dis.. 1986;8:368-379.
- [Google Scholar]
- Monomeric and dimeric copper(II) complexes of a novel tripodal peptide ligand: structures stabilized via hydrogen bonding or ligand sharing. Inorg. Chem.. 2000;39:5326-5332.
- [Google Scholar]
- Characterization of a yellow compound isolated from the marine sponge Phakellia flabellate. Chem. Commun.. 1980;3:435-436.
- [Google Scholar]
- Determination and analysis of the 2 A-structure of copper, zinc superoxide dismutase. J. Mol. Biol.. 1982;160:181-217.
- [Google Scholar]
- The coordinating properties of N-substituted thiosalicylaldimines with cobalt(II) and cobalt(III) organometallics containing an S2N2 quadridentate schiff base. Inorg. Nucl. Chem. Lett.. 1974;10:859-864.
- [Google Scholar]
- Induction of apoptosis by a novel copper-based anticancer compound, casiopeina II, in L1210 murine leukaemia and CH1 human ovarian carcinoma cells. Toxicol. In Vitro. 2000;14:1-5.
- [Google Scholar]
- Isomers and Tautomers of Hymenialdisine and Debromohymenialdisine. J. Nat. Prod. Lett.. 1996;9:57-64.
- [Google Scholar]
- Rearrangement of 4-aryl-1,2,4-triazine into the 4-amino derivatives. J. Heterocyclic Chem.. 1980;17:1733-1735.
- [Google Scholar]
- The role of NOS-mediated ROS accumulation in an early phase Cu-induced acute cytotoxicity in MCF-7 cells. Biometals. 2015;28:113-122.
- [Google Scholar]
Appendix A
Supplementary material
Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.arabjc.2016.04.013.
Appendix A
Supplementary material
Supplementary data 1
Supplementary data 1
